Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.63 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.63 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.63 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.63 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.63 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.63 |
| ▸ | CDC25B | P30305 | 2/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496963 | 1.00 | DYRK1A (0.63) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10093415 | 0.86 | DYRK1A (0.64) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL496976 | 0.86 | DYRK1A (0.64) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL497128 | 0.85 | DYRK1A (0.71) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL496852 | 0.85 | DYRK1A (0.71) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL497063 | 0.83 | CSNK2A2 (0.59) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL497062 | 0.83 | CSNK2A2 (0.59) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2788330 | 0.82 | DYRK1A (0.73) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2788327 | 0.82 | DYRK1A (0.73) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13196715 | 0.82 | DYRK1A (0.73) | DYRK1ADYRK1BCSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| EP-1807075-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | Applied Research Systems ARS Holding N.V. (AN) | 2007-07-18 | — | — | EP | claimed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | claimed |
| WO-2006040318-A2 | PI3 KINASE GAMMA INHIBITORS FOR THE TREATMENT OF ANAEMIA | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-04-20 | — | — | WO | claimed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| US-8106214-B2 | 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors | MERCK SERONO SA (CH) | 2012-01-31 | — | — | US | disclosed |
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1648452-B1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | MERCK SERONO SA (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1931424-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030360-A2 | P13K INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | disclosed |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1648452-A1 | 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005011686-A1 | 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | DYRK1A 362/4885DYRK1B 389/4885CSNK2A2 388/4885 |
| US-20070021447-A1 | 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors | PI4K2B, PI4KA, PTK2B | DYRK1A 2093/4885DYRK1B 1813/4885CSNK2A2 1038/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | DYRK1A 1259/4885DYRK1B 1267/4885CSNK2A2 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.